NEW YORK, Jan. 27, 2015
/PRNewswire/ -- IntelliCell BioSciences,
Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous stromal
vascular cells (SVCs) derived from the blood vessels found in
adipose tissue, today announced a license agreement for the
indication of Diabetes Mellitus.
Invigorcell will be filing an IND with the FDA for the
indication of Diabetes Mellitus.
According to Dr. Steven Victor CEO, "We are pleased to license
the indication of Diabetes Mellitus to Invigorcell who will be
conducting an IND with the FDA. With Joe
Krivulka and Marc Sandberg MD
leading the way I am sure we will see positive results with the FDA
in a short period of time, and be able to change the lives of
millions of diabetic patients."
Marc Sandberg, M.D., "Diabetes
has both a huge financial and personal burden around the world.
Restoring both Beta Cell and Metabolic function using Stromal
Vascular Fraction Cells derived from blood vessels found in adipose
tissue has a great potential to relieve suffering of people and
improve economies."
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using adult
autologous stromal vascular fraction cells (SVFCs) derived from the
blood vessels in the adult adipose tissue. IntelliCell BioSciences
has developed its own patented technology and protocol to separate
adult autologous vascular cells from adipose tissue without the use
of enzymes. IntelliCell will also be seeking to develop
technology-licensing agreements with technology developers,
Universities, and international business entities.
About Invigorcell
Invigorcell is a biotech company that will utilize the
technologies of IntelliCell BioSciences to develop innovative
treatments for the normalization of metabolism in both Type 1 and
Type 2 diabetes. Invigorcell is lead by Marc I. Sandberg, MD, FACP, CDE and Joe
Krivulka.
Dr. Sandberg is a Clinical Assistant Professor in the Department
of Internal Medicine at Temple
University School of Medicine and is a certified diabetes
Educator and board certified in Endocrinology, Diabetes and
Metabolism. He is the medical director for the Center for Nutrition
at Hunterdon Medical Center in Flemington, NJ. He
practices general endocrinology and diabetes, and was recognized as
a New Jersey Top Doc in 2005 and 2011-14. He has been involved in
numerous Phase II-IV pharmaceutical trials, has served on several
diabetes advisory product boards and lectures widely on
diabetes.
Mr. Joseph J. Krivulka is
Independent Director at Dance Biopharm, Inc., Chairman at Rouses
Point Pharmaceuticals LLC, Chairman & Chief Executive Officer
at Akrimax Pharmaceuticals LLC, and Independent Director at Nektar
Therapeutics. Mr. Krivulka was previously employed as Chief
Executive Officer by Triax Pharmaceuticals LLC, Independent
Director by Aeolus Pharmaceuticals, Inc., President by Reliant
Pharmaceuticals LLC, Chief Executive Officer by Bertek, Inc., and
Vice President by Mylan Laboratories, Inc. He also served on the
board at Ambrilia Biopharma, Inc., Biovail Corp., and Incara
Pharmaceuticals Corp. He received his undergraduate degree
from West Virginia Wesleyan
College.
Forward-Looking Statements
Certain statements set forth in this press release constitute
"forward-looking statements." Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "will reach," "will change," "will soon," "should,"
"could," "would," "may," "can" or words or expressions of similar
meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the
company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
arhodes@intellicellbiosciences.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/intellicell-biosciences-licenses-indication-for-diabetes-to-invigorcell-300026319.html
SOURCE IntelliCell BioSciences, Inc.